Literature DB >> 7577639

Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders.

M Kawakita1, Y Yonemura, H Miyake, T Ohkubo, N Asou, K Hayakawa, M Nakamura, T Kitoh, H Osawa, K Takatsuki.   

Abstract

The proto-oncogene, c-kit, encodes a transmembrane tyrosine kinase receptor (KIT) and plays an important role in haemopoiesis. We have identified a 95 kD soluble form of KIT (S-KIT) in culture supernatant of human megakaryoblastic cell line, CMK. To study the physiological significance of S-KIT, we have established a sensitive sandwich ELISA system. Serum samples from healthy individuals contained detectable amounts of S-KIT. Next, we determined a total of 220 samples from 134 patients with haemopoietic disorders. A considerable number of patients with acute myeloid leukaemia (AML), especially those with more immature phenotypes (M0, M1 or M2) had elevated levels of serum S-KIT. Those levels decreased to the normal range after effective chemotherapy. In chronic myeloid leukaemia, patients with myeloid blastic crisis showed markedly elevated levels of serum S-KIT. In contrast, S-KIT levels decreased in cases with either acute or chronic lymphoid leukaemia. There was a tendency for patients with severe aplastic anaemia to show decreased levels, but it was not significant. In myelodysplastic syndrome, S-KIT levels appeared to vary by subsets, with higher concentration in more advanced forms of the disease. Although the functional role of S-KIT is not yet elucidated, these results suggest that the serum S-KIT levels may reflect the pathological states of various haematological disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577639     DOI: 10.1111/j.1365-2141.1995.tb05239.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.

Authors:  Anjali S Advani
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

2.  Significance of stem cell factor and soluble KIT in patients with systemic lupus erythematosus.

Authors:  T Kitoh; H Ishikawa; S Sawada; K Koshino; Y Tokano; H Hashimoto; S Nakagawa
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Authors:  Samuel E Deprimo; Xin Huang; Martin E Blackstein; Christopher R Garrett; Charles S Harmon; Patrick Schöffski; Manisha H Shah; Jaap Verweij; Charles M Baum; George D Demetri
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

4.  Development of a Soluble KIT Electrochemical Aptasensor for Cancer Theranostics.

Authors:  Saeromi Chung; Jason K Sicklick; Partha Ray; Drew A Hall
Journal:  ACS Sens       Date:  2021-05-19       Impact factor: 9.618

5.  Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Dustan Kangave; Mohammed Mairaj Siddiquei; Karel Geboes
Journal:  J Diabetes Res       Date:  2013-03-10       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.